A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)

NCT04608838 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Ischemic Stroke

Interventions

BIOLOGICAL: JTR-161
BIOLOGICAL: Placebo

Sponsor

Teijin Pharma Limited